v3.26.1
SEGMENT INFORMATION (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment     1  
Number of reportable segments | segment     1  
Segment Reporting [Line Items]        
Royalty revenues $ 97 $ 69 $ 183 $ 271
Operating expenses        
Research and development 788 4,881 1,605 11,004
General and administrative 2,411 2,730 5,496 6,005
Operating loss (3,102) (7,542) (6,918) (16,738)
Income tax expense 0 0 0 0
Loss from continuing operations (2,899) (5,747) (6,484) (14,350)
Net loss (3,007) (5,755) (6,592) (14,366)
Reportable Segment        
Operating expenses        
Other segment items 348 750 821 1,779
General and administrative 2,411 2,730 5,496 6,005
Total operating expenses 3,199 7,611 7,101 17,009
Operating loss (3,102) (7,542) (6,918) (16,738)
Other income, net 203 1,795 434 2,388
Loss from continuing operations before income taxes (2,899) (5,747) (6,484) (14,350)
Income tax expense 0 0 0 0
Loss from continuing operations (2,899) (5,747) (6,484) (14,350)
Loss from discontinued operations, net of income taxes (108) (8) (108) (16)
Net loss (3,007) (5,755) (6,592) (14,366)
Reportable Segment | Royalty revenues        
Segment Reporting [Line Items]        
Royalty revenues 97 69 183 271
Reportable Segment | Repibresib (VYN201)        
Operating expenses        
Research and development 42 2,464 192 5,041
Reportable Segment | VYN202        
Operating expenses        
Research and development $ 398 $ 1,667 $ 592 $ 4,184